BioPharmSignal logoBioPharmSignal

Biotech News

TearCare Becomes the First and Only MGD Treatment Indicated to Improve Meibomian Gland Function in Patients with Evaporative Dry Eye Disease

Sight Sciences (SGHT)Sight SciencesCompany update

MENLO PARK, Calif., Aug. 19, 2026 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on developing and commercializing innovative interventional technologies intended to transform care and improve patients' lives, today announced that, effective August

Related news

SGHTSight Sciences2026-08-05 20:04 EST

Sight Sciences Announces Aetna Coverage for OMNI and SION Surgical Systems

SGHTSight Sciences2026-08-04 21:38 EST

Sight Sciences Receives FDA 510(k) Clearance of the OMNI Ultra Surgical System

HROWHarrow, Inc.2026-08-06 11:00 EST

Harrow Acquires Global Rights to TYRVAYA®, the First and Only FDA-Approved Nasal Spray for Dry Eye Disease

BLTEBelite Bio2026-08-11 20:01 EST

Belite Bio Announces U.S. Food and Drug Administration Acceptance and Priority Review of New Drug Application for Tinlarebant for the Treatment of Stargardt Disease Type 1

OTLKOutlook2026-07-24 18:40 EST

Outlook Therapeutics Announces LYTENAVA™ FDA Approval as the First and Only FDA-Approved Ophthalmic Bevacizumab for the Treatment of Wet AMD

OCGNOcugen2026-07-29 11:01 EST

Ocugen Announces that the U.S. Food and Drug Administration Has Granted OCU410 Regenerative Medicine Advanced Therapy (RMAT) Designation for Treatment of Geographic Atrophy, Secondary to Dry Age-Related Macular Degeneration

TCMDTactile Systems Technology, Inc.2026-07-13 12:00 EST

Tactile Medical Enters Exclusive U.S. Distribution Agreement with ElastiMed for its MyoSleeve™ Wearable Compression Device for VA and DoD Patients

ICCMIceCure Medical2026-08-06 12:05 EST

IceCure Medical Adds Adventist Health as U.S. Clinical Site for its Post-Marketing "ChoICE" Study for Low-Risk Breast Cancer Cryoablation Treatment

ICCMIceCure Medical2026-07-29 12:25 EST

IceCure: SIO Petitions NCCN to Include Cryoablation in Breast Cancer Treatment Guidelines, Citing IceCure's FDA Clearance of ProSense®

TARSTarsus Pharmaceuticals2026-07-08 20:05 EST

Tarsus Advances Eye Care Leadership Strategy with Acquisition of iRenix Medical and Late-Stage Asset IRX-101

View all latest news

Sight Sciences

Interventional Eye Care Sight Sciences develops minimally invasive and noninvasive technologies intended to address underlying causes of glaucoma and dry-eye disease. Glaucoma Systems OMNI and OMNI Edge are implant-free minimally invasive glaucoma-surgery systems that access Schlemm's canal and the trabecular meshwork. SION is a...

Recent company news

SGHTSight Sciences2026-08-19 11:05 EST

TearCare Becomes the First and Only MGD Treatment Indicated to Improve Meibomian Gland Function in Patients with Evaporative Dry Eye Disease

SGHTSight Sciences2026-08-05 20:05 EST

Sight Sciences Reports Second Quarter 2026 Financial Results

SGHTSight Sciences2026-08-05 20:04 EST

Sight Sciences Announces Aetna Coverage for OMNI and SION Surgical Systems

SGHTSight Sciences2026-08-04 21:38 EST

Sight Sciences Receives FDA 510(k) Clearance of the OMNI Ultra Surgical System

SGHTSight Sciences2026-07-22 20:05 EST

Sight Sciences to Report Second Quarter 2026 Financial Results on August 5, 2026

Stock data

Close
8.24 USD
Market cap
236.14M USD
Exchange
NASDAQ
Sector
MedTech
Location
United States